Long-lasting effect of a monophosphoryl lipid-adjuvanted immunotherapy to parietaria. A controlled field study

European Annals of Allergy and Clinical Immunology

Volumn 42, Issue 3, 2010, Pages 115-119

  Musarra, A ^a   Bignardi, D ^b   Troise, C ^b   Passalacqua, G ^c  

^a National Healthcare System   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Asthma; Immunotherapy; Long lasting effect; Monophosphoryl lipid adjuvant; Rhinitis

Indexed keywords

PHOSPHORYL LIPID A;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; IMMUNOTHERAPY; LOCAL SKIN REACTION; LUNG FUNCTION; MALE; PARIETARIA; RHINITIS; SKIN TEST; VISUAL ANALOG SCALE;

ADJUVANTS, IMMUNOLOGIC; ASTHMA; CONJUNCTIVITIS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; INJECTIONS, SUBCUTANEOUS; LIPID A; PARIETARIA; PROSPECTIVE STUDIES; RHINITIS;

EID: 77953893070     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bousquet J, Lockey R, Malling HJ (Ed). WHO Position Paper. Allergen Immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998; 53 (Suppl 44): 1-42.
2. Mistrello G, Brenna O, Roncarolo D, Falagiani P. Monomeric chemically modified allergens: immunologic and physicochemical caracterization. Allergy 1996; 51: 8-15.
3. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008 (18); 105 (46): 17908-12.
4. Wheeler AW, Marshall JS, Ulrich JT. Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001; 126 (2): 135-9.
5. Puggioni F, Durham SR, Francis JN Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 2005; 60: 678-84.
6. Allam J-P, Peng WM, Appel T, et al. The toll-like recepyor-4 agonist Mono-phosphoryl-lipid A enforces tolerogenic properties of oral mucosal Langherans cells. JACI 2008; 121: 368-74.
7. Drachenberg KJ,Wheeler AW, Stuebner P,Horak.A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections.Allergy 2001; 56 (6): 498-505.
8. Mothes N, Heinzkill M, Drachenberg KJ, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33 (9): 1198-208.
9. Passalacqua G, Durham SR. ARIA update: allergen immunotherapy. JACI 2007; 119 (4): 881-91.
10. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111: 1255-61.
11. Passalacqua G, Canonica GW. Long lasting efficacy of specific immunotherapy. Allergy 2002; 57: 275-6.
12. Bousquet J, Van Cauwenberge P. Allergic Rhinitis and its Impact on Asthma (ARIA) WHO Position Paper. J Allergy Clin Immunol 2001; 108 (5 Part 2): S 147-334.
13. Global Initiative for Asthma Management (GINA). www.ginasthma.org.
14. Hedlin G, Hheilborn H, Lilja G. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995; 57: 879-85.
15. Ariano R, Augeri M, Kroon L, Passalacqua G, Canonica GW. Long term allergoid immunotherapy to Parietaria: clinical and immunological effects in a double blind trial. Allergy 1999; 54: 313-9.
16. Durham SR,Walker SM, Varga EM. Long term clinical efficacy of grass pollen immunotherapy. N Eng J Med 1999; 468-75.
17. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006; 61: 198-201.
18. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a ten year prospective study. Clin Exp Allergy 2003; 33: 206-10.
19. Pajno GB, Barberio G, De Luca F,Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31: 1392-7
20. Thomas WR. Innovation in immunotherapy. Cl Exp Allergy 2009; 39: 450-4.
21. Drachenberg KJ. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl-lipid A (MPL) for children and adolescents. Allergol Immunopathol 2003; 31(5): 270-7.